Palombo H, Estapé J, Viñolas N, Grau J J, Mañé J M, Daniels M, Mellado B
University of Barcelona, Clinic Hospital, Medical Oncology Department, Spain.
Cancer Chemother Pharmacol. 1994;33(6):527-9. doi: 10.1007/BF00686513.
Chronic oral etoposide has shown activity in some metastatic refractory tumors. To test its activity in previously treated metastatic breast cancer patients, we started a study in 18 consecutive patients given etoposide orally at 50 mg/m2 daily for 21 days. A partial response was observed in 4 of 18 patients (22%); of the responding patients, 3 had visceral metastases and 1 had multiple bone metastases. Leukopenia of grade 3 or 4 was the main hematological toxic effect (23% of patients) and alopecia was the most important nonhematological toxicity. Chronic oral etoposide shows some activity in pretreated patients with metastatic breast cancer, with tolerance being good and toxicity, acceptable. Further studies of this drug given as first-line chemotherapy or in combination with other drugs can establish all its potential activity in this cancer.
长期口服依托泊苷已在一些转移性难治性肿瘤中显示出活性。为了测试其在先前接受过治疗的转移性乳腺癌患者中的活性，我们开展了一项研究，对18例连续患者每日口服依托泊苷50mg/m²，共21天。18例患者中有4例（22%）观察到部分缓解；在有反应的患者中，3例有内脏转移，1例有多发骨转移。3级或4级白细胞减少是主要的血液学毒性效应（占患者的23%），脱发是最重要的非血液学毒性。长期口服依托泊苷在先前接受过治疗的转移性乳腺癌患者中显示出一定活性，耐受性良好，毒性可接受。将这种药物作为一线化疗或与其他药物联合使用的进一步研究可以确定其在这种癌症中的所有潜在活性。
